RS Oncology Announces New Preclinical Data Show RSO-021 May

Data presented by Dr. Dean Fennell in an oral presentation at the IASLC 2023 World Conference on Lung Cancer in SingaporeRS Oncology’s novel therapy RSO-021, a first-in-class inhibitor of the antioxidant protein PRX3, was shown to reverse many of the features associated with aggressive mesothelioma tumor growthCAMBR...

Related Keywords

Leicester , United Kingdom , Massachusetts , United States , Cambridge , Cambridgeshire , Vermont , Singapore , Brian Cunniff , University Of Leicester , University Of Vermont Cancer Center , Cunniff Laboratory , Dean Fennell , Lung Cancer , Vermont Cancer , Achilles Heel , Future Directions , Spatial Transformation , Mesothelioma Involves ,